Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1671
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18274741 | COMPOSITIONS AND METHODS FOR PRODUCING GLYCO-MODIFIED VIRAL ANTIGENS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17261453 | ONCOLYTIC VIRUS CARRYING E-CADHERIN AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 18030465 | DETECTION OF ACE2 IgM AUTOANTIBODIES AS MARKERS OF SEVERITY AND MECHANISM IN COVID19 PATIENTS | Non-Final OA | The Johns Hopkins University |
| 18359154 | SELF-ASSSEMBLING NANOSTRUCTURE VACCINES | Final Rejection | University of Washington |
| 18040531 | MULTI-EPITOPE VACCINE | Non-Final OA | The Cleveland Clinic Foundation |
| 18286025 | METHODS, KITS, AND APPROACHES FOR VIRAL VACCINES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18029812 | VIRAL VACCINE COMPOSITIONS FOR INOCULATING A SUBJECT AGAINST A CORONAVIRUS, AN INFLUENZA VIRUS, OR BOTH | Non-Final OA | Atossa Therapeutics, Inc. |
| 18275773 | CIS-REPLICON CONSTRUCT | Non-Final OA | ZHENGZHOU UNIVERSITY |
| 18017752 | Antibody/Adjuvant Compositions and Methods of Immune Response Generation against Coronaviruses | Non-Final OA | University of Hawaii |
| 18488422 | Recombinant Ranavirus, Methods of Production, and Its Use As A Mammalian Expression System | Non-Final OA | The Trustees of the California State University |
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | Non-Final OA | Inovio Pharmaceuticals, Inc. |
| 18033980 | NUCLEIC ACIDS, PROTEINS, AND VACCINES OF SARS-COV-2 | Non-Final OA | City of Hope |
| 18251620 | DNA ENCODED NANOPARTICLES AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 18042796 | INTRADERMAL MERS-CoV VACCINE | Final Rejection | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY |
| 18494219 | VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE | Final Rejection | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. |
| 18420532 | FORMULATIONS OF ANTIBODY MOLECULES TO DENGUE VIRUS | Final Rejection | VISTERRA, INC. |
| 18030892 | HERPESVIRUS POLYEPITOPE VACCINES | Non-Final OA | The Council of the Queensland Institute of Medical Research |
| 18021792 | ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | The Scripps Research Institute |
| 18556612 | ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS, METHODS AND USE THEREOF | Non-Final OA | LA JOLLA INSTITUTE FOR IMMUNOLOGY |
| 18275925 | ADJUVANTED MUCOSAL SUBUNIT VACCINES FOR PREVENTING SARS-COV-2 TRANSMISSION AND INFECTION | Non-Final OA | The United States of America, as represented by the Secretary, Depart. of Health and Human Services |
| 16631692 | APHERESIS METHODS AND USES | Final Rejection | SPARK THERAPEUTICS, INC. |
| 18077713 | Human Cytomegalovirus Immunogenic Composition | Non-Final OA | Sanofi Pasteur |
| 18250694 | METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE | Non-Final OA | BIOVAXYS INC. |
| 18249904 | FUSION PROTEIN AND APPLICATION THEREOF | Non-Final OA | BEIJING ABZYMO BIOSCIENCES CO., LTD. |
| 18030633 | VACCINE COMPOSITIONS | Non-Final OA | Virothera Limited |
| 18013663 | FUSION GENE, RECOMBINANT NOVEL CORONAVIRUS HIGH-EFFICIENCY IMMUNE DNA VACCINE, CONSTRUCTION METHOD AND USE THEREOF | Final Rejection | Aurora Genevac Biotech Co., Ltd. |
| 17821884 | ADENO-ASSOCIATED VIRUS FORMULATIONS | Final Rejection | Oxford Biomedica (US) LLC |
| 17796368 | Virus-Like Particle Vaccines for Opioid Drugs | Final Rejection | ARIZONA BOARD OF REGENTS, FOR AND ON BEHALF OF NORTHERN ARIZONA UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy